Psychedelic Therapy: The Science and the Future of Mental Health

A growing body of science is pointing to a new frontier in healing, one that expands on conventional mental health treatments. Psychedelic therapy is an emerging, evidence-backed field that is reshaping how researchers, clinicians, and individuals understand the mind, trauma, and the possibility of lasting change. It’s a new paradigm for mental health research and treatment.

In this blog, you will learn what psychedelic therapy is, which psychedelic compounds are currently recognized as therapeutically relevant in the academic literature, how traditional cultures have used these substances for centuries, and what the clinical research reveals about their benefits.

You will also gain a clear understanding of how psychedelic interventions differ from conventional treatment options — including the degree and durability of symptom change — and what a typical treatment protocol looks like. Whether you are a curious observer or someone actively exploring healing options, this post offers a grounded, science-informed perspective on one of the most significant developments in modern mental health.

What Is Psychedelic Therapy?

Psychedelic therapy refers to the clinical and ceremonially guided use of psychoactive compounds to facilitate psychological healing, emotional processing, and shifts in perspective. Psychedelic-assisted therapy typically involves a therapeutic objective, careful preparation, a supervised dosing session, and integration work afterward to consolidate the insights and experiences that arise.

Clinically, psychedelic therapy falls within the broader category of experiential and biologically-informed psychotherapy — an approach that works with the brain's neuroplasticity and the mind's capacity for reorganization under altered states of consciousness. It shares conceptual ground with somatic therapies, depth psychology, and trauma-focused approaches, while introducing a neurochemical catalyst that can dramatically accelerate the therapeutic process.

The emerging consensus in the scientific literature positions psychedelic therapy not as a recreational or casual practice, but as a targeted, intentional intervention. As someone who studied psychology and worked in the field of mental health for several years, I’m deeply inspired by the results being shown in clinical settings.

Because of the nature of many of these compounds, however, the perspective I encourage holding is this: once the therapeutic goal has been achieved, these compounds have done their work. They are instruments of healing, not sources for recreational use— a distinction that honors both their power and their proper context.

The Most Clinically Studied Psychedelics in Mental Health Treatment

A growing body of peer‑reviewed, clinically grounded research has begun to clarify which psychedelic and psychedelic‑adjacent compounds show the most therapeutic promise. While many substances are discussed in popular culture, only a select group currently has published human data substantial enough to inform clinical practice and guide regulated therapeutic use. In the following section, I focus on the compounds with the strongest evidence base to date—psilocybin, MDMA, ketamine, ayahuasca, LSD, ibogaine, and mescaline—and summarize what contemporary research shows about their therapeutic effects.

Psilocybin Therapy

Psilocybin, the active compound in "magic mushrooms," is currently one of the most extensively studied psychedelics in clinical settings. It works primarily as a serotonin 5-HT2A receptor agonist, producing profound alterations in perception, cognition, and sense of self. Research from leading institutions — including Johns Hopkins University, Imperial College London, and NYU — has documented significant therapeutic effects for depression, anxiety, and addiction.

Notably, Carhart-Harris et al. (2021) published findings demonstrating that psilocybin was at least as effective as the antidepressant escitalopram in treating major depressive disorder, with rapid onset and durable effects. The FDA has granted psilocybin "Breakthrough Therapy" designation for both treatment-resistant depression and major depressive disorder.

MDMA Therapy

MDMA (3,4-Methylenedioxymethamphetamine), commonly associated with recreational use, has demonstrated powerful therapeutic properties when used in controlled clinical settings for post-traumatic stress disorder (PTSD). Unlike classical psychedelics, MDMA primarily enhances the release of serotonin, dopamine, and oxytocin, reducing fear responses while increasing feelings of trust and openness.

Mitchell et al. (2021) found in a Phase 3 clinical trial that MDMA-assisted therapy led to a remarkable 67% of participants no longer meeting PTSD criteria after treatment, compared to 32% in the placebo group. The FDA has also designated MDMA-assisted therapy as a Breakthrough Therapy for PTSD.

Ketamine Therapy

Ketamine is currently the only psychedelic-adjacent compound with full FDA approval for clinical use in the form of esketamine (Spravato) for treatment-resistant depression. As an NMDA receptor antagonist, it works through a distinct mechanism from classical psychedelics, producing rapid antidepressant effects — often within hours.

Murrough et al. (2013) demonstrated ketamine's superiority over midazolam in reducing depressive symptoms, with effects appearing within 24 hours. While its psychedelic properties are subtler than psilocybin or ayahuasca, its altered-state experience is nonetheless integral to its therapeutic mechanism.

Ayahuasca Plant Therapy

Ayahuasca is a plant-based brew traditionally prepared from the Banisteriopsis caapi vine and the Psychotria viridis leaf. It contains both DMT (dimethyltryptamine) and monoamine oxidase inhibitors (MAOIs), which allow the DMT to become orally active.

Clinically, ayahuasca has demonstrated antidepressant, anti-addictive, and anxiolytic properties. Palhano-Fontes et al. (2019) conducted the first randomized placebo-controlled trial of ayahuasca and found rapid antidepressant effects in treatment-resistant depression, with significant reductions in depressive symptoms observed within days.

Mescaline (Peyote)

Mescaline is the primary psychoactive alkaloid in peyote (Lophophora williamsii), a cactus with a documented ceremonial history spanning nearly 6,000 years among indigenous peoples of North America and Mesoamerica. Like psilocybin and LSD, mescaline acts primarily as a serotonin 5-HT2A receptor agonist, producing altered states of consciousness that typically last 8 to 12 hours — one of the longer active windows among the classic psychedelics (Agin-Liebes et al., 2021).

While mescaline remains among the least formally studied compounds in the current psychedelic research renaissance, peer-reviewed data are beginning to substantiate what centuries of ceremonial use have long suggested. A 2021 survey-based study drawing on a sample of 452 adults with histories of clinical conditions, found that between 68% and 86% of participants reported subjective improvement in their most memorable mescaline experience across a range of mental health domains — including depression (86%), anxiety (80%), PTSD (76%), and alcohol and drug use disorders (68–76%; Agin-Liebes et al., 2021). Improvements were correlated with the intensity of mystical experience and psychological insight reported during the session, mirroring the mechanisms identified in psilocybin and MDMA research.

A landmark study also found no evidence of psychological or cognitive deficits among Native Americans using peyote regularly in a ceremonial context, supporting its long-term safety profile (Halpern et al., 2005). Mescaline has been described as having a notably navigable experiential quality relative to other psychedelics, with less than 1% of respondents in survey research reporting adverse psychological reactions — a characteristic that may carry meaningful implications for clinical tolerability (Vamvakopoulou et al., 2023). While randomized controlled trials are still forthcoming, the compound's preliminary data, combined with its extensive ethnopharmacological record, have led prominent researchers to call it "the forgotten psychedelic" — one whose clinical application is only beginning to be rigorously examined (Vamvakopoulou et al., 2023).

LSD  

LSD(Lysergic Acid Diethylamide), one of the most potent psychedelics known, acts primarily on serotonin receptors and produces extended altered states lasting 8–12 hours. While research was suppressed for decades following its scheduling in the 1970s, recent trials have renewed scientific interest.

Gasser et al. (2014) published findings showing that LSD-assisted psychotherapy reduced anxiety in patients with life-threatening illness, with effects maintained at a 12-month follow-up. LSD's long duration makes it particularly suited for deep psychological work.

Ibogaine

Ibogaine, derived from the Tabernanthe iboga root native to West Africa, occupies a unique position among psychedelics due to its extreme potency and duration — sessions can last 24 to 36 hours. It acts on multiple receptor systems including opioid, NMDA, and sigma receptors. Ibogaine has shown particular promise in treating opioid dependence, with Brown and Alper (2018) documenting significant reductions in withdrawal symptoms and cravings. Due to cardiovascular risks, ibogaine is among the most strictly monitored compounds, requiring medical screening and supervision.

Ibogaine has also emerged as a particularly promising intervention for military veterans, with traumatic brain injury (TBI). Following a single ibogaine session combined with magnesium to protect the heart, conducted under medical monitoring, participants experienced immediate and significant improvements across PTSD, depression, anxiety, and overall functioning — with effects persisting at the one-month follow-up endpoint (Kratter & Williams, 2024)

Traditional and Cultural Uses of Psychedelic Plants

Long before clinical trials, indigenous cultures around the world had developed sophisticated ceremonial frameworks for working with psychedelic plants — frameworks that often included the very elements modern research has validated: preparation, intentionality, relational support, and integration.

Ayahuasca ceremonies have been conducted for thousands of years in the Amazon basin by indigenous peoples of Peru, Brazil, Colombia, and Ecuador. Facilitated by trained healers known as curanderos or ayahuasceros, these ceremonies are deeply embedded in spiritual and communal contexts, used for healing, divination, and connection to ancestral wisdom. The Santo Daime and União do Vegetal religious traditions in Brazil have incorporated ayahuasca into formal church practice, and both have received legal protections in Brazil and the United States (Labate & Jungaberle, 2011).

Peyote, a cactus containing mescaline, has been used ceremonially by Native American peoples — particularly the Huichol (Wixáritari) of Mexico and members of the Native American Church — for centuries. These ceremonies are conducted with strict ritual protocols and are recognized as protected religious practice under U.S. federal law for enrolled tribal members.

Psilocybin mushrooms were used in ritual healing contexts in pre-Columbian Mesoamerica, documented among the Mazatec people of Oaxaca, Mexico, where curandera María Sabina brought velada ceremonies to broader awareness in the mid-twentieth century.

Ibogaine comes from a tradition of use in the Bwiti spiritual traditions of Gabon and Cameroon, where multi-day initiatory ceremonies are conducted as rites of passage and healing.

What unites these traditions is a shared understanding that these substances are powerful catalysts for healing and transformation — not casual pleasures — and that they require a container of intention, guidance, and meaning to be used safely and beneficially. This understanding has informed the structure of modern clinical protocols.

Clinical Benefits of Psychedelic Therapy: What the Research Shows

Across multiple peer‑reviewed studies, certain compounds have demonstrated measurable therapeutic effects in some of the most challenging areas of mental health care. These include treatment‑resistant depression and anxiety, PTSD and trauma‑related symptoms, and addiction and substance use disorders. The following section highlights what current clinical evidence suggests about how psychedelics may support healing in each of these domains.

Treatment-Resistant Depression and Anxiety

One of the most compelling areas of psychedelic research is its application for individuals who have not responded to conventional treatments. For treatment-resistant depression, psilocybin has demonstrated effects that outpace standard antidepressants in some trials. Davis et al. (2021) found that two sessions of psilocybin produced large, rapid, and sustained decreases in depressive symptoms, with 71% of participants showing a clinically significant response at four weeks. You will find few conventional pharmacological treatments with comparable outcomes at this speed.

PTSD and Trauma

The MDMA-assisted therapy research represents a paradigm shift in trauma treatment. The compound's ability to reduce amygdala reactivity while enhancing interpersonal trust allows individuals to revisit traumatic memories without becoming overwhelmed — a state sometimes called the "therapeutic window." The Phase 3 trials by Mithoefer et al. and Mitchell et al. (2021) have produced effect sizes that are among the largest ever reported in PTSD treatment research, with effects maintained at 12 and 18-month follow-ups.

Addiction and Substance Use Disorders

Psychedelics have shown striking efficacy in treating addiction across multiple substances. Johnson et al. (2014) found that psilocybin-assisted treatment for nicotine addiction produced a 67% abstinence rate at six months — a figure that dwarfs the 35% typically achieved by combination nicotine replacement therapy and varenicline. For alcohol use disorder, Bogenschutz et al. (2015) found significant reductions in drinking following psilocybin sessions, with effects correlating with the intensity of the mystical-type experience. These outcomes suggest that psychedelics may address addiction at a deeper level than symptom management alone.

Psychedelic Therapy: Clinical and Cultural Use — An Important Distinction

As psychedelic therapy gains mainstream momentum, it is worth holding a clear distinction between its clinical application and its cultural use. In clinical settings, psychedelic interventions are tightly regulated, carefully screened, and embedded in a therapeutic framework. Participants typically undergo extensive psychological assessment to rule out contraindications. Sessions are conducted with trained therapists present throughout, in carefully designed environments, and are followed by structured integration sessions.

This is not a space for casual exploration. The clinical model understands these compounds as medicine — potent, purposeful, and context-dependent. A perspective widely shared among researchers and experienced facilitators is that once the therapeutic goal has been achieved, the work with these substances is complete. Psychedelics, in this framing, are not maintenance therapies or ongoing aids; they are catalysts for a process of transformation that you then carry forward through integration, embodiment, and applied change. Using them beyond this purpose — whether for recreation or out of curiosity — falls outside the therapeutic model and outside the scope of what the research endorses.

Cultural ceremonial use, while often equally intentional and structured, operates within different frameworks and without the clinical screening, trained trauma-informed therapists, and emergency medical access that characterize regulated clinical settings. Both have value, but they are not interchangeable — and recognizing that distinction is part of using these tools wisely.

The Science of Lasting Change: Memory Reconsolidation and Neuroplasticity

One of the most fascinating questions about psychedelic therapy is why its effects are so durable. A single session of psilocybin or MDMA-assisted therapy can produce changes that persist for months or years — a pattern that is highly unusual in pharmacological or even psychotherapeutic interventions. Emerging research points to several complementary mechanisms.

Memory reconsolidation theory, an approach I write about in my book Anything You Want, offers one compelling explanation. When a memory is retrieved, it enters a brief window of instability before being re-stored — a process called reconsolidation. During this window, the emotional valence of the memory can be altered. MDMA, in particular, appears to facilitate the retrieval of traumatic memories while simultaneously downregulating the fear response, creating optimal conditions for the emotional signature of trauma memories to be updated (Ot'alora G. et al., 2018; Sessa et al., 2021). This is not symptom regulation — it is a fundamental rewriting of how the memory is stored and experienced.

Carhart-Harris and Friston (2019) proposed the REBUS (Relaxed Beliefs Under Psychedelics) model, which suggests that psychedelics temporarily loosen the brain’s reliance on rigid top‑down predictions — the deeply ingrained cognitive and emotional habits that sustain depression, addiction, and anxiety — while increasing sensitivity to bottom‑up sensory information. In this state, the brain becomes more flexible and more capable of updating outdated beliefs. This aligns with a growing body of evidence showing that psychedelics open a window of heightened neuroplasticity in which new patterns of thinking, feeling, and relating can be formed.

Supporting this, Castrén and Bhattacharya (2019) noted that psychedelics promote the expression of BDNF (brain‑derived neurotrophic factor) and stimulate structural remodeling of neural circuits. These processes closely resemble what happens during critical developmental periods — the early‑life windows when the brain is especially malleable, rapidly forming and pruning connections in response to experience. During these periods, learning is accelerated, emotional patterns are shaped, and relational templates are formed. Psychedelics appear to temporarily recreate aspects of this heightened plasticity in the adult brain, allowing entrenched patterns to be revisited and reorganized under supportive therapeutic conditions.

In practical terms, this means psychedelic therapy isn’t masking symptoms — it appears to restructure the neural architecture underlying them. This is a qualitatively different mechanism from most psychiatric medications, which require continuous use to maintain their effect.

Psychedelic Interventions vs. Conventional Treatment: Degree and Durability of Change

To appreciate what makes psychedelic therapy remarkable, it is useful to compare it directly with conventional treatment approaches. Standard antidepressants (SSRIs and SNRIs) typically require 4–8 weeks to reach therapeutic effect and require continuous daily use to maintain benefits. In terms of who they help, response rates of roughly 40–60% mean that SSRIs and SNRIs do work — and work meaningfully — for more than half the people they are prescribed to. That is not a trivial finding; for millions of people, these medications have been genuinely life-changing. The challenge is that the remaining 40–60% experience little to no meaningful relief, and even among those who do respond, many report partial improvement rather than full remission — meaning symptoms are reduced but not resolved.

Cognitive Behavioral Therapy (CBT) and other evidence-based psychotherapies show durable effects with dedicated practice over months, but require ongoing effort and are often limited by access, cost, and therapeutic relationship quality. In plain terms, effect sizes across standard psychotherapy meta-analyses for depression ranging from d = 0.58 to 0.80 mean that the average person completing a full course of psychotherapy ends up better off than roughly 70–79% of untreated individuals — a genuinely meaningful outcome that reflects real relief for many people. What this range also reveals, however, is that psychotherapy's effectiveness is ceiling-bound by the very human factors that make it valuable in the first place: the number of sessions a person can afford, whether a skilled therapist is accessible, and whether a strong enough therapeutic alliance develops to do deep work.

Psychedelic interventions, by contrast, typically involve one to three sessions and produce effect sizes that are among the largest reported in psychiatric literature. The psilocybin trial by Davis et al. (2021) reported effect sizes of d = 2.5 for depressive symptom reduction — exceptionally large by any clinical standard. In this study, more than half of participants no longer met clinical criteria for depression four weeks after just two psilocybin sessions.

The MDMA PTSD trials reported effect sizes of d = 0.91 in favor of MDMA over placebo at primary outcome, with an within-group effect size of d = 2.1 for MDMA participants specifically (Mitchell et al., 2021). In plain terms, after just three MDMA-assisted therapy sessions conducted over 18 weeks, 67% of participants no longer met the diagnostic criteria for PTSD at all, and 33% met the criteria for full remission — meaning their symptoms had not merely reduced but had fallen below the clinical threshold entirely. By comparison, only 32% of the placebo group no longer met the diagnostic criteria for PTSD and just 5% achieved remission over the same period. To appreciate what those numbers mean for the people behind them: the majority of individuals who had been living with severe, chronic PTSD — with an average diagnosis duration of over 14 years — were no longer diagnosable after three sessions of treatment. Critically, these outcomes are measured weeks to months after the final session, with no ongoing use of the compound — a durability profile that is without precedent in psychiatric medicine.

The contrast is not simply in magnitude but in mechanism: conventional treatments generally act through continuous neurochemical modulation. Psychedelic therapy appears to catalyze a one-time or brief reorganization of psychological structures, with the individual's own integration doing the ongoing work of change. This places psychedelic therapy closer to transformative experiential therapies than to pharmacological maintenance — a distinction with significant implications for how you understand and approach your own healing journey.

What Does a Typical Psychedelic Treatment Protocol Look Like?

Clinical research has converged on relatively consistent treatment structures across compounds, with specific variations based on the substance and target condition.

Preparation Sessions

Most protocols include 2–4 preparatory therapy sessions lasting 60–90 minutes each. These sessions establish therapeutic rapport, explore the participant's history and intentions, set expectations for the dosing experience, and develop personalized frameworks for integration. Preparation has been identified as a significant predictor of positive outcomes (Watts et al., 2017).

Dosing Session(s)

Psilocybin protocols typically involve 1–3 dosing sessions using moderate to high doses (20–30 mg in most trials), each lasting 6–8 hours, with therapists present throughout. Sessions are conducted in a comfortable, aesthetically intentional room, with participants wearing eye shades and listening to a curated music playlist to support inward attention. The interval between sessions is typically 2–4 weeks.

MDMA-assisted therapy for PTSD uses 2–3 dosing sessions of MDMA (typically 80–120 mg with a possible supplemental 40–60 mg dose), each lasting 8 hours, with two therapists present. Ketamine infusion protocols vary from single to a series of 6 infusions over 2–3 weeks. Ibogaine, due to its duration and intensity, is typically administered in a single session.

Integration Sessions

Following each dosing session, 3–4 integration therapy sessions are standard. These sessions help you process the experiences, emotions, and insights that emerged, anchor meaningful changes in daily behavior, and address any difficult material. Researchers increasingly recognize integration as the phase where therapeutic outcomes are consolidated and sustained (Bathje et al., 2022).

Psychedelic Therapy on the World Stage: A Global Policy Shift Underway

The momentum behind psychedelic therapy is no longer confined to research laboratories or academic journals — it is reshaping mental health policy across the globe. What was once dismissed as a relic of counterculture is now being recognized by governments, regulatory bodies, and public health systems as a legitimate and urgently needed category of therapeutic intervention. The driving force behind this shift is unambiguous: a growing body of peer-reviewed, replicated, and clinically rigorous research that has produced some of the largest effect sizes ever recorded in psychiatric treatment literature.

In 2023, Australia became the first country in the world to formally integrate psychedelic medicine into its healthcare framework when its Therapeutic Goods Administration reclassified both psilocybin and MDMA from prohibited substances to controlled therapeutic drugs — making them legally prescribable for treatment-resistant depression and PTSD respectively, under an Authorized Prescriber Scheme requiring ethics committee oversight. Australia has since extended this commitment by publicly funding psychedelic-assisted therapy for its military population.

Canada has taken a parallel path through its Special Access Program, granting compassionate access to psilocybin and MDMA for patients with serious or life-threatening conditions, while Alberta became the first province to legalize multiple psychedelic compounds for therapeutic use, and Quebec became the first to publicly fund psilocybin-assisted psychotherapy.

The United States, through the FDA’s Breakthrough Therapy designations for psilocybin and MDMA, has accelerated its own research pipeline — and ketamine in its esketamine formulation is already FDA-approved and in active clinical use nationwide.

The momentum extends well beyond these early adopters. In 2025, the Czech Republic’s Chamber of Deputies passed landmark legislation to legalize medical psilocybin with an overwhelming 142 of 159 votes in favor, positioning Czechia to become the first EU member state to broadly legalize a psychedelic medicine. Germany established the EU’s first psilocybin compassionate use program the same year.

The Netherlands’ parliamentary health committee formally recommended fast-tracking MDMA-assisted psychotherapy for PTSD through its public health system, describing the evidence as pointing to a treatment that is both effective and relatively safe. In the United Kingdom — home to some of the world’s foremost psychedelic research institutions — the government responded to parliamentary pressure by removing the requirement for controlled drug research licenses, clearing a significant barrier to expanded clinical trials, with broader access expected to follow.

The direction of travel is unmistakable: the science is not merely promising, it is definitive enough to move the policy needle across regulatory systems on four continents. For those who need these treatments most, that global recognition is not an abstraction — it is an expanding doorway to healing that, for many, has no equivalent.

Conclusion: Psychedelic Therapy as a Validated Path Toward Healing and Mental Health

Psychedelic therapy represents one of the most significant advances in mental health treatment in decades. The research is no longer preliminary — it is peer-reviewed, replicated, and, in several cases, supported by regulatory Breakthrough Therapy designations.

Whether you are living with treatment-resistant depression, PTSD, addiction, or existential distress, the evidence suggests that psychedelic interventions can offer a depth and durability of change that few conventional approaches match.

What makes this field particularly compelling is its alignment with a view of healing that you may already resonate with: that lasting change does not come from perpetually managing symptoms, but from transforming the patterns underneath them. Psychedelic therapy, used with intention and clinical structure, offers a pathway to that transformation — not as a shortcut, but as a catalyst. The work still belongs to you. These compounds simply make it possible to do in hours what might otherwise take years.

As this field continues to mature, staying informed means following the science, engaging with qualified practitioners, and holding the distinction between therapeutic use and recreational experimentation with clarity and respect. The future of mental health is being written now — and you are part of the conversation.

As I wrote earlier in the blog, I’m deeply inspired by the results psychedelic therapy makes available to those who need it most. I’m optimistic about the continued inclusion of these effective compounds by governments and health‑care providers so that more people can permanently recover and reengage with their lives. I fully believe that life isn’t about pain and suffering, and the more we do to alleviate what we can alleviate, the more people can move toward flourishing. It's why I'm adamant about writing about the solutions that do work like sulforaphane and moringa, red light therapy, PEMF, energy medicine, and bright light therapy. As I write in my book Manifesting Health and Longevity, many solutions already exist that can mean the realization of total mental and physical well-being.

This blog is intended for informational and educational purposes. Always consult a qualified healthcare professional before beginning any new therapeutic protocol.

References

Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021). Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacology & Translational Science, 4(2), 543–552.

Bathje, G. J., Majeski, E., & Kudowor, M. (2022). Psychedelic integration: An analysis of the concept and its practice. Frontiers in Psychology, 13, 824077.  

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C. R., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299.  

Brown, T. K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse, 44(1), 24–36.  

Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402–1411.  

Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316–344.  

Castrén, E., & Bhattacharya, S. (2019). Antidepressant activity of ketamine: Highlights from basic research. Bipolar Disorders, 21(8), 713–720.  

Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5), 481–489.  

Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. Journal of Nervous and Mental Disease, 202(7), 513–520.  

Halpern, J. H., Sherwood, A. R., Hudson, J. I., Yurgelun-Todd, D., & Pope, H. G. (2005). Psychological and cognitive effects of long-term peyote use among Native Americans. Biological Psychiatry, 58(8), 624–631.

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983–992.  

Kratter, I. H., & Williams, N. R. (2024). Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine, 30(2), 373–381.

Labate, B. C., & Jungaberle, H. (Eds.). (2011). The internationalization of ayahuasca. LIT Verlag.

Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot'alora G., M., Garas, W., Palatin, C., Gorman, I., Bhatt, S., Bhatt, S., Quevedo, S., Mayo, C., Woolley, J., Tzarfaty, K., Ammar, M., Sarid-Segal, O., & Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled Phase 3 study. Nature Medicine, 27(6), 1025–1033.  

Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., Charney, D. S., & Mathew, S. J. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. American Journal of Psychiatry, 170(10), 1134–1142.  

Ot'alora G., M., Grigsby, J., Poulter, B., Van Derveer, J. W., Giron, S. G., Jerome, L., Feduccia, A. A., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2018). 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. Journal of Psychopharmacology, 32(12), 1295–1307.  

Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., Tófoli, L. F., de Oliveira Silveira, G., Yoncheva, Y. N., Castellanos, F. X., Tófoli, L. F., & Araújo, D. B. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine, 49(4), 655–663.  

Sessa, B., Sakal, C., O'Brien, S., & Nutt, D. (2021). First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. Journal of Psychopharmacology, 35(4), 375–383.  

Vamvakopoulou, I. A., Narine, K. A. D., Campbell, I., Dyck, J. R. B., & Nutt, D. J. (2023). Mescaline: The forgotten psychedelic. Neuropharmacology, 222, 109294.

Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients' accounts of increased 'connectedness' and 'acceptance' after psilocybin for treatment-resistant depression. Journal of Humanistic Psychology, 57(5), 520–564.  

About Kidest OM

Kidest OM is a personal development coach, author, and speaker specializing in conscious evolution, emotional intelligence, and manifestation. Her personal development books and online courses integrate modern psychology, neuroscience, and consciousness studies to help individuals cultivate resilience, self-awareness, and authentic empowerment. A seasoned business consultant and former corporate executive, Kidest brings both scientific and strategic insight to personal transformation and spiritual growth. Her writing explores how emotional mastery, self-belief, and mindset alignment drive performance and fulfillment across all areas of life. Explore her personal development books and online courses to elevate your awareness, align your purpose, and thrive with greater resilience.